|
|||||
|
|
| Latest Insider Trading | Top Insider Trading Recent Week | Top 10% Owner Trading Recent Week | Filter
|
| Ticker | Owner | Relationship | Date | Transaction | Cost |
#Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| IRWD | Shetzline Michael | SVP, CMO, Head-Res&Drug | Feb 10 '25 | Sale | 1.76 | 41,269 | 72,633 | 554,007 | Feb 12 09:00 PM |
| IRWD | Shetzline Michael | Officer | Feb 10 '25 | Proposed Sale | 1.94 | 42,274 | 82,012 | Feb 07 04:20 PM | |
| IRWD | Shetzline Michael | CMO,SVP,Head-Res&Drug | May 20 '24 | Sale | 6.45 | 16,128 | 104,026 | 413,719 | May 22 04:05 PM |
| IRWD | Shetzline Michael | CMO,SVP,Head-Res&Drug | Mar 08 '24 | Option Exercise | 0.00 | 34,936 | 0 | 429,847 | Mar 12 04:05 PM |
| IRWD | Shetzline Michael | CMO,SVP,Head-Res&Drug | Feb 12 '24 | Sale | 15.24 | 38,618 | 588,538 | 340,484 | Feb 14 08:53 PM |
| IRWD | Shetzline Michael | CMO,SVP,Head-Res&Drug | May 22 '23 | Sale | 10.12 | 10,324 | 104,479 | 321,131 | May 24 04:05 PM |
| IRWD | Shetzline Michael | CMO,SVP,Head-Res&Drug | Feb 27 '23 | Sale | 11.41 | 9,468 | 108,030 | 271,440 | Mar 01 06:21 PM |
| IRWD | Shetzline Michael | CMO,SVP,Head-Res&Drug | Feb 28 '23 | Sale | 11.31 | 9,854 | 111,449 | 261,586 | Mar 01 06:21 PM |
| IRWD | Shetzline Michael | CMO,SVP,Head-Res&Drug | May 23 '22 | Sale | 11.50 | 10,583 | 121,704 | 266,245 | May 25 04:05 PM |
| IRWD | Shetzline Michael | CMO,SVP,Head-Res&Drug | Feb 28 '22 | Sale | 10.77 | 17,607 | 189,627 | 195,380 | Mar 02 04:01 PM |
| IRWD | Shetzline Michael | CMO,SVP,Head-Res&Drug | Nov 23 '21 | Sale | 11.58 | 13,776 | 159,526 | 183,661 | Nov 24 04:08 PM |
| IRWD | Shetzline Michael | CMO, SVP & Head of Drug Devt. | May 24 '21 | Sale | 12.25 | 2,077 | 25,443 | 197,437 | May 26 04:05 PM |
| IRWD | Shetzline Michael | CMO, SVP & Head of Drug Devt. | Feb 26 '21 | Sale | 9.11 | 4,439 | 40,439 | 160,859 | Mar 02 04:44 PM |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite